MESO Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland...

Stats
Dagens volum	282 718
Gjennomsnittsvolum	2.28M
Markedsverdi	855.93M
EPS	$0 ( 2024-03-25 )
Neste inntjeningsdato	( $-0.320 ) 2024-05-23
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-8.52
ATR14	$0.0190 (0.25%)

Volum Korrelasjon

Lang: 0.16 (neutral)

Kort: 0.76 (moderate)

Signal:(56.007) Neutral

Mesoblast Limited Korrelasjon

10 Mest positive korrelasjoner
PFSW	0.949
LABP	0.944
DSGN	0.941
NN	0.94
CTIC	0.936
PRVB	0.93
CDXC	0.927
PESI	0.927
IDN	0.92
SCTL	0.919

10 Mest negative korrelasjoner
LIAN	-0.939
SBNYP	-0.928
LUCD	-0.923
LUNA	-0.922
NOVN	-0.912
NLSP	-0.909
AEY	-0.908
PRFT	-0.908
AZ	-0.907
EZGO	-0.905

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Mesoblast Limited Korrelasjon - Valuta/Råvare

-0.64
( weak negative )

-0.74
( moderate negative )

0.00
( neutral )

-0.60
( weak negative )

0.50
( neutral )

0.66
( moderate )

Mesoblast Limited Økonomi

Annual	2023
Omsetning:	$7.50M
Bruttogevinst:	$-20.23M (-269.72 %)
EPS:	$-1.050

FY	2023
Omsetning:	$7.50M
Bruttogevinst:	$-20.23M (-269.72 %)
EPS:	$-1.050

FY	2022
Omsetning:	$10.21M
Bruttogevinst:	$-20.55M (-201.21 %)
EPS:	$-1.330

FY	2021
Omsetning:	$7.46M
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-0.817

Financial Reports:

No articles found.

Mesoblast Limited

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company's products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection; Rexlemestrocel-L to treat advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV for the treatment of biologic refractory rheumatoid arthritis diabetic nephropathy. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.